Genomiconomics.com
Executive Summary
With the free-fall in dot com stocks, money has flowed--with a vengeance--into biotech. But the valuations are not sustainable: most of the new companies are shooting for a market far too small to support even half of the new competitors, and trying to sell only portions of what drug companies want to buy.
You may also be interested in...
Coronavirus Notebook: EMA Issues Guidance On Development Of Variant Vaccines, EU Leaders Urge Production Ramp-Up
A batch of AstraZeneca/Oxford University coronavirus vaccines has arrived in Ghana, the first country in the world to receive vaccines via the COVAX Facility.
Start-Up Scanwell Adds Another Collaboration, Targets Home COVID-19 Testing With BD
Scanwell Health, a leader in smartphone-enabled home diagnostics tests, has announced a partnership with Beckton Dickson.
Execs On The Move: Slew Of Directorships At Zimmer And 908 Devices
908 Devices, Zimmer Biomet and Ortho Clinical Diagnostics have all appointed new directors, Biolase promotes executive vice president to chief executive officer role, and more.
Need a specific report? 1000+ reports available
Buy Reports